# CANAGLIFLOZIN
> **ANDA210451** · Abbreviated New Drug Application (Generic) · Sponsor: TEVA PHARMS USA · Approved 2022-06-14
## Drug
- **FDA Application Number:** ANDA210451
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** CANAGLIFLOZIN
- **Generic name:** Canagliflozin
- **Active ingredients:** CANAGLIFLOZIN
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** TEVA PHARMS USA
- **First approval:** 2022-06-14
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210451)
---
*AI Analytics · CC0 1.0*